---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-252200"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2025-10-28T23:59:59+00:00"
generated_at: "2026-05-17T01:54:02.998220+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aldeyra positive Phase 2 ADX-629 in alcohol-hepatitis; pipeline focuses on ADX-248/ADX-246; cash runway into H2 2027

## Summary
- ADX-629 Phase 2 trial in mild-to-moderate alcohol-associated hepatitis showed significant improvement in MELD score (P=0.001), triglycerides (P<0.0001), and CRP (P<0.0001).
- Pipeline focused on next-generation RASP modulators ADX-248 (metabolic inflammation, IND 2026) and ADX-246 (dry AMD, IND 2026); ADX-629 development discontinued.
- Cash runway extended into second half of 2027 due to pipeline prioritization.
- No serious adverse events reported in the ADX-629 trial; drug was well tolerated.

## SEC filing metadata
- accession: 0001193125-25-252200
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2025-10-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000119312525252200/0001193125-25-252200-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000119312525252200/aldx-20251028.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-252200
- JSON: https://secwatch.observer/filing/0001193125-25-252200.json
- Plain text: https://secwatch.observer/filing/0001193125-25-252200.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.